| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Net income | -21.9 | -11.3 |
| EPS (diluted, $ a share) | $-0.28 | $-0.21 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: CADL. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Candel Therapeutics, Inc.: key numbers
- Share price
- $5.40Close, Nov 17
- Market cap
- $424M
- Shares outstanding
- 78.45MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Candel Therapeutics, Inc.
All →Candel Therapeutics Capital Raise
Candel Therapeutics entered into a Second Amended and Restated Open Market Sale Agreement with Jefferies LLC to establish a new at-the-market (ATM) equity facility. The agreement allows the company to sell up to $50 million of common stock from time to time, in addition to the $50 million previously sold under a prior 2025 agreement.
- Counterparty
- Jefferies LLC
Candel Therapeutics Financial Results
Candel Therapeutics reported third quarter 2026 financial results, ending the period with $203.1 million in cash which is expected to fund operations into Q2 2028. The company updated its regulatory timeline, now planning to submit a Biologics License Application (BLA) for aglatimagene in prostate cancer in mid-2027 following assay refinement. Recent clinical progress included three poster presentations at the SITC 41st Annual Meeting showcasing data across its prostate, lung, and glioma programs.
- Term
- Q3 2026
“During the quarter we continued to execute well and make significant progress across the business, as we build the foundation to potentially become a commercial-stage biopharma company.”
Paul Peter Tak, M.D., Ph.D., FMedSci, President and CEO
“On the clinical side, we were honored to have had three posters accepted for presentation at SITC, featuring data on aglatimagene in localized prostate cancer and non-small cell lung cancer, and linoserpaturev in recurrent high-grade glioma. Together, the new biomarker data provide mechanistic support for the systemic effect and long-term clinical outcomes observed in our phase 3 trial of aglatimagene in patients with intermediate- to high-risk localized prostate cancer.”
Paul Peter Tak, M.D., Ph.D., FMedSci, President and CEO